Clinical Trials Browser

Breast Neoplasms × Ado-Trastuzumab Emtansine × 90 days × Clear all

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT06324357 2026-05-26

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

Phase 1/2 Recruiting

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Breast Neoplasms, Colorectal Neoplasms

NCT03587740 2026-05-18

ATOP TRIAL: T-DM1 in HER2 Positive Breast Cancer

Phase 2 Active not recruiting

111 enrolled 20 charts

Breast Neoplasms

NCT06663787 2026-05-13

HER2 CR

Active not recruiting

Breast Neoplasms, Neoplasm Metastasis, Neoplasm, Residual

NCT01042379 2026-05-06

I-SPY

Phase 2 Recruiting

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT04733118 2026-04-29

PHERGAIN-2

Phase 2 Active not recruiting

Breast Neoplasms

NCT04893109 2026-04-24

ATEMPT 2.0: Adjuvant T-DM1 vs TH

Phase 2 Recruiting

Breast Neoplasms

NCT04158258 2026-04-23

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Active not recruiting

Breast Neoplasms

NCT02326974 2026-04-17

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Phase 2 Active not recruiting

164 enrolled 19 charts

Breast Neoplasms

NCT02390427 2026-04-09

Phase Ib Dose-escalation Trial of Taselisib (GDC-0032) in Combination With Anti-HER2 Therapies in Participants With Advanced HER2+ Breast Cancer

Phase 1 Completed

Breast Neoplasms